Peregrine and Stason Enter Into Agreement for Innovative Tumor Necrosis Therapy (TNT) Technologies

Three Presentations at AACR Annual Meeting Show Breadth of Applications for Peregrine's Innovative Phospholipid-Targeting Technologies

New Preclinical Breast Cancer Study Shows Peregrine's PS-Targeting Antibodies Can Reverse Tumor-Induced Immune Suppression

New Study Shows Combining Peregrine's Bavituximab With an Apoptosis-Inducing Agent Can Eradicate Tumors in a Model of Advanced Breast Cancer

Peregrine Announces Data From Four Clinical Studies Will Be Presented at 2010 ASCO Annual Meeting

Peregrine Launches Investigator-Sponsored Trial Program

Peregrine Pharmaceuticals Reports Data from Newly Published Research Reinforcing Potential of Targeting PS in HIV Infection

Avid Bioservices and Halozyme Therapeutics Expand Commercial Supply Relationship with New Manufacturing Agreements

Peregrine Announces Data From Four Studies to be Presented at American Association for Cancer Research Annual Meeting

Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter Fiscal Year 2010